3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
154
Neoplasm Metastasis
10
Prostatic Neoplasms, Castration-Resistant
8
Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Breast Neoplasms
6
Metastatic Castration Resistant Prostate Cancer
5
Prostate Cancer Metastatic
4
Metastatic Castration-Resistant Prostate Cancer
4
Urogenital Neoplasms
2
Prostatic Diseases
2
Neoplasms by Site
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Genital Neoplasms, Male
2
Castration-resistant Prostate Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Stage II Prostate Adenocarcinoma
1
Salivary Glands Tumors
1
Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
1
Prostate Adenocarcinoma
1
Pharmacogenetic Study
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Oligometastatic Prostate Carcinoma
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoadjuvant Therapy
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Interventions
padeliporfin
5
Lycopene
3
pembrolizumab
2
darolutamide
2
Vitamin E
2
Tea
2
Selenium
2
Cholecalciferol
2
relatlimab
1
palladium-bacteriopheophorbide
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Therapeutics
1
Surveys and Questionnaires
1
Sugars
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Nivolumab
1
Mitomycin
1
Intraoperative Neurophysiological Monitoring
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
CP protocol
1
Blood Specimen Collection
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Male Urogenital Diseases
×
Abiraterone Acetate
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled